ES2820585T3 - Composiciones y métodos anti-HCMV - Google Patents
Composiciones y métodos anti-HCMV Download PDFInfo
- Publication number
- ES2820585T3 ES2820585T3 ES15859814T ES15859814T ES2820585T3 ES 2820585 T3 ES2820585 T3 ES 2820585T3 ES 15859814 T ES15859814 T ES 15859814T ES 15859814 T ES15859814 T ES 15859814T ES 2820585 T3 ES2820585 T3 ES 2820585T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- mmol
- pharmaceutically acceptable
- acceptable salt
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C1=C*C(*(CC2)CC3=C2C=CCC3)=N1)C1=CC2=*CC*=C2C=C1 Chemical compound CC(C1=C*C(*(CC2)CC3=C2C=CCC3)=N1)C1=CC2=*CC*=C2C=C1 0.000 description 11
- CSHVMJCNPSBZMW-UHFFFAOYSA-N CC(c([s]1)cnc1Cl)(C1=CC2=NC=[I]N=C2C=C1)O Chemical compound CC(c([s]1)cnc1Cl)(C1=CC2=NC=[I]N=C2C=C1)O CSHVMJCNPSBZMW-UHFFFAOYSA-N 0.000 description 1
- PTOAWAAPKXOFQA-UHFFFAOYSA-N CC1SC(Cl)=NC1 Chemical compound CC1SC(Cl)=NC1 PTOAWAAPKXOFQA-UHFFFAOYSA-N 0.000 description 1
- GEHSHYYNLMLVME-UHFFFAOYSA-N CN(C(c(cc1)cc2c1nccn2)=O)OC Chemical compound CN(C(c(cc1)cc2c1nccn2)=O)OC GEHSHYYNLMLVME-UHFFFAOYSA-N 0.000 description 1
- HYQAGTCCMAWUDC-UHFFFAOYSA-N N=C(CC1)CC(C2C3C2)=C1C=CC3C#N Chemical compound N=C(CC1)CC(C2C3C2)=C1C=CC3C#N HYQAGTCCMAWUDC-UHFFFAOYSA-N 0.000 description 1
- JGQDBVXRYDEWGM-UHFFFAOYSA-N OC(c1cc2nccnc2cc1)=O Chemical compound OC(c1cc2nccnc2cc1)=O JGQDBVXRYDEWGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
- G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
- G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
- G07B15/02—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points taking into account a variable factor such as distance or time, e.g. for passenger transport, parking systems or car rental systems
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07B—TICKET-ISSUING APPARATUS; FARE-REGISTERING APPARATUS; FRANKING APPARATUS
- G07B15/00—Arrangements or apparatus for collecting fares, tolls or entrance fees at one or more control points
- G07B15/06—Arrangements for road pricing or congestion charging of vehicles or vehicle users, e.g. automatic toll systems
- G07B15/063—Arrangements for road pricing or congestion charging of vehicles or vehicle users, e.g. automatic toll systems using wireless information transmission between the vehicle and a fixed station
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Finance (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Devices For Checking Fares Or Tickets At Control Points (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077804P | 2014-11-10 | 2014-11-10 | |
| PCT/US2015/059746 WO2016077232A2 (en) | 2014-11-10 | 2015-11-09 | Anti-hcmv compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2820585T3 true ES2820585T3 (es) | 2021-04-21 |
Family
ID=55955245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15859814T Active ES2820585T3 (es) | 2014-11-10 | 2015-11-09 | Composiciones y métodos anti-HCMV |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10556894B2 (enExample) |
| EP (1) | EP3218373B1 (enExample) |
| JP (1) | JP6698083B2 (enExample) |
| CN (1) | CN107438435B (enExample) |
| AU (1) | AU2015346657B9 (enExample) |
| CA (1) | CA2967316C (enExample) |
| ES (1) | ES2820585T3 (enExample) |
| IL (2) | IL252190B2 (enExample) |
| MX (1) | MX377327B (enExample) |
| WO (1) | WO2016077232A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2820585T3 (es) * | 2014-11-10 | 2021-04-21 | Evrys Bio Llc | Composiciones y métodos anti-HCMV |
| CA3079396A1 (en) * | 2017-10-18 | 2019-04-25 | Evrys Bio, Llc | Broad spectrum antiviral compositions and methods |
| CN120078779A (zh) * | 2020-01-24 | 2025-06-03 | 威斯康星州医药大学股份有限公司 | 用于抑制疱疹病毒的组合物 |
| US20240109883A1 (en) * | 2020-12-31 | 2024-04-04 | Evrys Bio, Llc | Anti-Tumor Compositions and Methods |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2612187B1 (fr) * | 1987-03-12 | 1989-07-21 | Sanofi Sa | Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant |
| US5232921A (en) * | 1987-03-12 | 1993-08-03 | Sanofi | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| CN1207094A (zh) * | 1995-12-29 | 1999-02-03 | 贝林格尔·英格海姆药物公司 | 具有抗疱疹病毒特性的苯基噻唑衍生物 |
| ATE227279T1 (de) | 1995-12-29 | 2002-11-15 | Boehringer Ingelheim Pharma | Phenyl thiazol derivate mit antiherpesvirus eigenschaften |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| US6993423B2 (en) * | 2002-12-19 | 2006-01-31 | General Motors Corporation | Method for adjusting vehicle cockpit devices |
| DE102005033103A1 (de) | 2005-07-15 | 2007-01-25 | Bayer Healthcare Ag | Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene |
| JP2010518014A (ja) * | 2007-01-31 | 2010-05-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用な2−アミノピリジン誘導体 |
| CA2693495A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| KR101000148B1 (ko) * | 2008-10-08 | 2010-12-10 | 현대자동차주식회사 | 차량의 자동요금정산시스템 및 장치 |
| DK2312536T3 (da) * | 2009-10-15 | 2013-10-14 | Kapsch Trafficcom Ag | Køretøjsapparat til et vejafgiftssystem |
| US8321264B2 (en) * | 2009-10-16 | 2012-11-27 | Kapsch Trafficcom Ag | Method and apparatus for displaying toll charging parameters |
| WO2012160015A1 (en) * | 2011-05-23 | 2012-11-29 | Sanofi | Process for the preparation of deuterated compounds containing n-alkyl groups |
| US20140074566A1 (en) * | 2012-09-11 | 2014-03-13 | James K. McCoy | Remote Sensing of Vehicle Occupancy |
| US20140229568A1 (en) * | 2013-02-08 | 2014-08-14 | Giuseppe Raffa | Context-rich communication between a device and a vehicle |
| US20150335657A1 (en) | 2014-05-05 | 2015-11-26 | The Trustees Of Princeton University | Methods for Modulating Sirtuin Enzymes |
| ES2820585T3 (es) * | 2014-11-10 | 2021-04-21 | Evrys Bio Llc | Composiciones y métodos anti-HCMV |
-
2015
- 2015-11-09 ES ES15859814T patent/ES2820585T3/es active Active
- 2015-11-09 IL IL252190A patent/IL252190B2/en unknown
- 2015-11-09 AU AU2015346657A patent/AU2015346657B9/en active Active
- 2015-11-09 JP JP2017526068A patent/JP6698083B2/ja active Active
- 2015-11-09 CA CA2967316A patent/CA2967316C/en active Active
- 2015-11-09 IL IL308138A patent/IL308138A/en unknown
- 2015-11-09 CN CN201580071073.2A patent/CN107438435B/zh active Active
- 2015-11-09 WO PCT/US2015/059746 patent/WO2016077232A2/en not_active Ceased
- 2015-11-09 MX MX2017006043A patent/MX377327B/es active IP Right Grant
- 2015-11-09 EP EP15859814.4A patent/EP3218373B1/en active Active
- 2015-11-09 US US15/525,504 patent/US10556894B2/en active Active
-
2019
- 2019-12-22 US US16/724,343 patent/US11358961B2/en active Active
-
2022
- 2022-01-13 US US17/574,884 patent/US20220135556A1/en active Pending
-
2024
- 2024-01-30 US US18/426,855 patent/US20250174051A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL252190B1 (en) | 2023-12-01 |
| EP3218373A4 (en) | 2018-06-13 |
| WO2016077232A3 (en) | 2016-08-18 |
| US20220135556A1 (en) | 2022-05-05 |
| US11358961B2 (en) | 2022-06-14 |
| JP2017535549A (ja) | 2017-11-30 |
| MX2017006043A (es) | 2018-02-13 |
| NZ731753A (en) | 2020-11-27 |
| WO2016077232A2 (en) | 2016-05-19 |
| US20180291016A1 (en) | 2018-10-11 |
| AU2015346657B2 (en) | 2019-12-19 |
| IL308138A (en) | 2023-12-01 |
| CA2967316A1 (en) | 2016-05-19 |
| IL252190A0 (en) | 2017-07-31 |
| US20250174051A1 (en) | 2025-05-29 |
| AU2015346657B9 (en) | 2020-01-16 |
| AU2015346657A1 (en) | 2017-06-01 |
| CN107438435B (zh) | 2020-12-04 |
| MX377327B (es) | 2025-03-07 |
| EP3218373B1 (en) | 2020-07-22 |
| CA2967316C (en) | 2021-12-14 |
| US20200140429A1 (en) | 2020-05-07 |
| US10556894B2 (en) | 2020-02-11 |
| EP3218373A2 (en) | 2017-09-20 |
| IL252190B2 (en) | 2024-04-01 |
| CN107438435A (zh) | 2017-12-05 |
| JP6698083B2 (ja) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7817972B2 (ja) | 広域スペクトルの抗ウイルス組成物及び方法 | |
| ES2326750T3 (es) | 5-carboxiamido pirazoles y (1,2,4) triazoles como agentes antivirales. | |
| US20220135556A1 (en) | Anti-hcmv compositions and methods | |
| US20210040049A1 (en) | Anti-hcmv compositions and methods | |
| RU2813125C2 (ru) | Противовирусные композиции широкого спектра действия и способы | |
| BR112020007879B1 (pt) | Composições antivirais de amplo espectro e métodos | |
| NZ731753B2 (en) | Anti-hcmv compositions and methods |